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PURPOSE: Triple-negative breast cancer (TNBC), a subtype of breast cancer that is oestrogen receptor (ER) negative, progesterone
receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative, has a poor prognosis. Although a
correlation between E-cadherin expression level and outcome has been demonstrated among all types of breast cancer, little is
known about the significance of E-cadherin expression levels in TNBC.
METHODS: A total of 574 patients who had undergone a resection of a primary breast cancer except for invasive lobular carcinomas
were enrolled in this study. Expressions of ER, PR, HER2, and E-cadherin were assessed by immunohistochemistry. We examined the
association between TNBC and other clinicopathological variables and evaluated the significance of the E-cadherin expression.
RESULTS: Among the 574 breast cancer cases, 123 (21.4%) revealed a triple-negative phenotype. Patients with TNBC experienced
more frequent lymph node metastasis (P¼0.024) and a poorer prognosis (Po0.001) in comparison with non-TNBC patients.
Triple-negative breast cancer was an independent prognostic factor. Reduced levels of E-cadherin were observed in 238 (41.5%) of
the 574 breast cancer cases. E-cadherin reduction was significantly frequent in cases of TNBC (Po0.001) and lymph node metastasis
(P¼0.032). Furthermore, in the 123 TNBC cases, the prognosis of patients with an E-cadherin-negative expression was significantly
worse than that of E-cadherin-positive patients (P¼0.0265), especially for those in clinical stage II (P¼0.002). A multivariate logistic
regression analysis showed a reduction of the E-cadherin expression to be an independent prognostic factor (P¼0.046).
CONCLUSION: E-cadherin expression may be a useful prognostic marker for classifying subgroups of TNBC.
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Human breast cancers represent a heterogeneous group of
tumours that display significant diversity with regard to clinical
behaviour, outcome, and response to therapy (Perou et al, 2000;
Abd El-Rehim et al, 2005; Mattie et al, 2006). The prognosis and
management of breast cancer is influenced by the status of
oestrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) of the tumour. The
mortality of breast carcinoma is decreasing because of recent
developments in diagnostic techniques and therapies; however, the
mortality of triple-negative breast cancer (TNBC), a subtype of
breast cancer that is ER negative, PR negative, and HER2 negative,
remains high (Sorlie et al, 2001, 2003; Rakha et al, 2006; Bauer
et al, 2007). In addition to being a clinically heterogeneous disease,
breast cancer is also molecularly heterogeneous. Breast cancer
subgroups are primarily defined by ER and HER2 expression,
although the different prognostic signatures have not yet been
clearly evaluated in these different molecular subgroups (Derksen
et al, 2006). As molecular biological characterisation of these
groups is still uncertain, the characterisation of TNBC may be
important for evaluating patients’ outcomes and for developing
a molecular-based medicine treatment strategy.
E-cadherin is a calcium-regulated homophilic cell–cell adhesion
molecule. E-cadherin inactivation is one of the changes that
characterise the invasive breast cancer phenotype. Transfection of
cDNA encoding E-cadherin into highly invasive mouse mammary
tumour cell lines resulted in decreased invasiveness and metastasis
(Meiners et al, 1998). Previous studies have shown correlations
between decreased levels of E-cadherin expression and distant
metastases, as well as patient outcomes (Siitonen et al, 1996;
Charpin et al, 1998; Heimann et al, 2000). However, little is
known about the E-cadherin expression levels of TNBC. To
reduce mortality from TNBC, there is a need to examine and
characterise tumours of poor prognosis, to predict their biology,
to ensure adequate therapy, and to improve patients’ outcome
(Mahler-Araujo et al, 2008). In this study, we classified 123 cases of
breast cancer with the triple-negative phenotype from 574 breast
carcinomas. We addressed the significance of clinicopathological
features and E-cadherin expression to identify additional prog-
nostic markers that can identify tumours with more aggressive
behaviour.
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Figure 1 (A) Immunohistochemical determination of E-cadherin. (B) Correlation between triple-negative phenotype and overall survival or disease-free
interval in the breast cancer series. (C) Probability of survival of breast cancer patients in relation to the E-cadherin expression. (D) The overall survival of
patients with resectable breast cancer according to the clinical stage.
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sMATERIALS AND METHODS
Patients
This study investigated a consecutive series of 574 cases of
sporadic invasive breast carcinoma, except for invasive lobular
carcinomas. All patients underwent a curative operation of a
mastectomy or a conservative surgery with axillary lymph node
dissection at our department from 2000 to 2006. All of the patients
who had undergone conservative breast surgery received post-
operative radiotherapy to the residual breast. Each patient was
treated with suitable adjuvant therapy postoperatively according to
the stage of the disease. This study was approved by the Osaka City
University ethics committee. Informed consent was obtained from
all patients before entry. The disease-free interval was defined as
the interval in months, from the date of the primary surgery to the
first local recurrence or distant metastasis. The overall survival was
the time, in weeks, from the date of the primary surgery to the time
of breast cancer-related death. Tumours were confirmed histo-
pathologically and staged according to the TNM classification
(Singletary and Greene, 2003).
Immunohistochemistry
All tissues were fixed in 10% neutral-buffered formalin immedi-
ately after surgical resection and embedded in paraffin using
standard protocols (Meiners et al, 1998; Mattie et al, 2006). In
brief, the slides were deparaffinised and were heated for 20min at
1051C by autoclave in Target Retrieval Solution (Dako, Carpinteria,
CA, USA). Sections were then incubated with 3% hydrogen
peroxide to block endogenous peroxidase activity. Thereafter,
sections were incubated in 10% normal goat or rabbit serum to
reduce non-specific antibody binding. Primary monoclonal anti-
bodies were directed against ER (clone 1D5, dilution 1:80; Dako,
Cambridge, UK), PR (clone PgR636, dilution 1:100; Dako), HER2
(Hercep Test, Dako), and E-cadherin (clone NCH-38, dilution
1:200; Dako). Tissue sections were incubated with each antibody
for 70min at room temperature or overnight at 41C. After washing
in phosphate-buffered saline (PBS), tissues were incubated with
horseradish peroxidase-conjugated anti-rabbit or anti-mouse Ig
polymer as a second antibody (Envision kit, Dako) for 30min at
room temperature, according to the manufacturer’s instructions.
The slides were treated with streptavidin–peroxidase reagent, and
were incubated in PBS diaminobenzidine and 1% hydrogen
peroxide v/v, followed by counterstaining with Mayer’s haema-
toxylin. Positive and negative controls for each marker were
used according to the supplier’s data sheet (Dako). Immuno-
histochemical scoring was performed in a blind manner. The
cutoff for ER positivity and PR positivity was X10% positive
tumour cells with nuclear staining. Human epidermal growth
factor receptor 2 positive was defined as either HER2 gene
amplification or scored as 3þ. E-cadherin antibody stained the
membrane intensely and the cytoplasm of cancer cells weakly.
E-cadherin expression was semi-quantitatively analysed according
to the percentage of cells showing membrane positivity: 0, 0–10%;
1þ, 10–30%; 2þ, 30–70%; 3þ, 470%. E-cadherin expression
was considered positive when scores were X2, and negative when
scores were p1 (Figure 1A). A case with cytoplasmic staining only
was determined as E-cadherin negative.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 statistical
software (SPSS Inc., Chicago, IL, USA). We examined the asso-
ciation between TNBC and other clinicopathological variables, and
the significance of different prognostic markers using w
2 test, and
w
2 test for trend as appropriate. The association with survival was
analysed initially by Kaplan–Meier plot and log-rank test and also
with Cox regression analysis to adjust for other prognostic
indicators. A P-value of o0.05 was considered significant. Cutoff
values for different biomarkers included in this study were chosen
before statistical analysis.
RESULTS
Identification and clinicopathological features of 123
TNBCs
In this study, 574 cases of breast carcinomas were analysed for the
three markers (namely ER, PR, and HER2). Of these cases, 123
Table 1 Clinicopathologic feature of 123 triple-negative breast cancers
in 574 breast cancers
Parameters
TNBC
(n¼123)
non-TNBC
(n¼451) P-value
Age at operation (years)
p55 58 (22.7%) 198 (77.3%) 0.520
455 65 (20.4%) 253 (79.6 %)
Pathological stage
I 41 (16.1%) 214 (83.9%) 0.005
II and III 82 (25.7%) 237 (74.3%)
pTumour size (cm)
p2 55 (17.5%) 259 (82.5%) 0.012
42 68 (26.2%) 192 (73.8%)
pLymph node status
Negative 74 (18.7%) 321 (81.3%) 0.024
Positive 48 (27.1%) 129 (72.9%)
Lymph-vascular invasion
Negative 71 (18.5%) 313 (81.5%) 0.015
Positive 52 (27.4%) 138 (72.6%)
Histological type
IDC 108 (22.6%) 370 (77.4%) 0.129
Special type 15 (15.6%) 81 (84.4%)
Abbreviations: TNBC¼triple-negative breast cancer; IDC¼invasive ductal
carcinoma.
Table 2 Univariate and multivariate analyses with respect to overall
survival in 574 all breast cancers
Univarite
analysis
Multivariate
analysis
Parameters
Odds
ratio
95%
CI P-value
Odds
ratio
95%
CI P-value
Pathological stage
I vs II and III 2.199 0.987–4.898 0.049 1.122 0.360–3.495 0.842
Lymph node status
Negative vs
positive
3.083 1.541–6.169 0.001 2.341 0.873–6.281 0.091
Subtype
TNBC vs
non-TNBC
0.099 0.045–0.220 o0.001 0.144 0.061–0.341 o0.001
E-cadherin
Negative
vs positive
0.213 0.096–0.472 o0.001 0.517 0.218–1.230 0.136
Abbreviations: CI¼confidence interval; TNBC¼triple-negative breast cancer.
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s(21.4%) showed a triple-negative phenotype (ER negative, PR
negative, and HER2 negative). Table 1 shows the clinicopatho-
logical features of TNBC, as compared with those of non-TNBC.
The 123 patients with TNBC had a median age of 58 years (range,
26–93 years). A statistically significant difference was observed
between TNBC and non-TNBC with regard to the degree of
pathological stage (P¼0.005), tumour size (P¼0.012), lymph
node metastasis (P¼0.024), and lymphatic invasion (P¼0.015).
The median overall survival of the 574 patients was 45.7 months
(range, 5.8–72 months), and the median time of disease-free
interval was 42.5 months (range, 4.8–72 months). Patients with
TNBC experienced significantly poorer outcomes in terms of
overall survival (Po0.001, log rank) and disease-free interval
(Po0.001, log rank) in comparison with patients with non-TNBC
(Figure 1B). A univariate analysis of the 574 breast cancer cases
demonstrated significant correlations between overall survival
and reduction in E-cadherin (Po0.001), TNBC (Po0.001), cancer
stage (P¼0.049), lymph node disease (P¼0.001), and lymphatic
invasion (P¼0.040). On the basis of a multivariate logistic
regression analysis of the tumour stage, lymph node status,
lymphatic invasion, TNBC, and E-cadherin expression, the TNBC
subtype was the only variable of independent prognostic
significance in the 574 breast cancer cases (Table 2).
E-cadherin expression in breast cancer
Reduced E-cadherin expression was observed in 238 (41.5%) of the
574 breast cancer patients (Table 3). The reduction in E-cadherin
was significantly frequent in cases of TNBC (Po0.001) and
lymph node metastasis (P¼0.032). E-cadherin-negative patients
experienced significantly poorer outcomes in terms of overall
survival (Po0.001, log rank) and disease-free interval (Po0.001,
log rank) in comparison with patients who were E-cadherin
positive (Figure 1C). Our findings indicated that the prognosis of
E-cadherin-negative cases was significantly poorer than that of
E-cadherin-positive cases at stage I, II, and III (Figure 1D).
Although no significant association between E-cadherin expression
and clinicopathological parameters was identified in the 123
TNBC cases (Table 3), TNBC patients with E-cadherin-negative
expression experienced significantly poorer outcomes in terms of
overall survival (P¼0.0265, log rank) and disease-free interval
(P¼0.0125, log rank) than did E-cadherin-positive patients
(Figure 2A). With regard to the clinical stage, the prognosis of
E-cadherin-negative cancer patients was significantly poorer than
that of E-cadherin-positive cancer patients with regard to overall
survival (P¼0.002) and disease-free interval (P¼0.002) in stage II
(Figures 2B and C). The disease-free interval in E-cadherin-
negative cancer patients was shorter than that of E-cadherin-
positive cancer patients in stage I and III, although no significant
difference in prognosis was observed between the two groups.
On the basis of a univariate analysis of 123 TNBC cases, overall
survival significantly correlated with E-cadherin expression
(P¼0.028) and lymph node metastasis (P¼0.026). A multivariate
logistic regression analysis of the 123 TNBC cases also showed that
the reduction of E-cadherin expression significantly correlated
with overall survival (P¼0.046), thus suggesting that E-cadherin is
an independent prognostic factor for TNBC (Table 4).
DISCUSSION
The frequency of TNBC is reported to be 15–26% of all breast
cancers (Carey et al, 2006; Rakha et al, 2007). Among the 574
breast cancer cases in this study, we identified 123 (21.4%) patients
with the triple-negative phenotype. These TNBC patients showed
frequent lymph node metastasis and lymphatic invasion and
experienced significantly poorer outcomes in comparison with
non-TNBC patients. On the basis of multivariate logistic regression
Table 3 Correlations between E-cadherin expression and clinicopathological parameters in 574 all breast cancers in 123 triple-negative breast cancers
All breast cancers (n¼574) TNBC (n¼123)
Parameters Negative (n¼238) Positive (n¼336) P-value Negative (n¼90) Positive (n¼33) P-value
ER and HER2 status
TNBC 90 (73.2%) 33 (26.8%) o0.001 Not Not
Non-TNBC 148 (32.8%) 303 (67.2%) determined determined
Age at operation (years) 1
p55 100 (39.0%) 156 (61.0%) 0.295 40 (69.0%) 8 (31.0%) 0.320
455 138 (43.4%) 180 (56.6%) 50 (77.0%) 15 (23.0%)
Pathological stage
I 100 (39.2%) 155 (60.8%) 0.328 29 (70.0%) 12 (30.0%) 0.666
II and III 138 (43.3%) 181 (56.7%) 61 (74.4%) 21 (25.6%)
pTumour size (cm)
p2 129 (41.1%) 185 (61.5%) 0.839 40 (72.7%) 15 (27.3%) 0.920
42 109 (42.0%) 151 (58.0%) 50 (73.5%) 18 (26.5%)
pLymph node status
Negative 153 (38.5%) 244 (61.5%) 0.032 52 (69.3%) 23 (30.7%) 0.213
Positive 85 (48.0%) 92 (52.0%) 38 (79.2%) 10 (20.8%)
Lymph-vascular invasion
Negative 152 (39.6%) 232 (60.4%) 0.156 52 (74.3%) 18 (25.7%) 0.844
Positive 86 (45.3%) 104 (54.7%) 38 (71.7%) 15 (28.3%)
Histological type
IDC 193 (40.0%) 285 (60.0%) 0.238 77 (71.3%) 31 (28.7%) 0.208
Special type 45 (46.9%) 51 (53.1%) 13 (86.7%) 2 (13.3%)
Abbreviations: ER¼oestrogen receptor; HER2¼human epidermal growth factor receptor 2; TNBC¼triple-negative breast cancer; IDC¼invasive ductal carcinoma.
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sanalysis of the 574 breast cancer cases, the TNBC subtype was
demonstrated to be an independent prognostic factor. These
findings confirmed that TNBC has high biological malignancy, as
previously reported (Sorlie et al, 2001, 2003; Rakha et al, 2007).
A reduction of E-cadherin expression was associated with poor
outcome (Po0.001) and lymph node metastasis (P¼0.032). This
finding suggested that the decrease of E-cadherin expression might
be linked to the development of lymph node metastases in breast
cancer. Although some studies have shown a correlation between
E-cadherin expression and outcome in breast cancer (Lipponen
et al, 1994; Siitonen et al, 1996), Rakha et al (2007) observed no
correlation between survival rates and E-cadherin expression.
Differences in antibodies, cutoff values, or race are possible
reasons for discrepancies among these studies. In this study,
E-cadherin antibody was clearly localised at the cell–cell
boundaries. Genetic or epigenetic alterations are reported to be
one of the reasons for the reduction of E-cadherin expression.
Sporadic breast cancer is reported to show a frequent loss
of heterozygosity at 16q22.1 wherein E-cadherin is located
(Cleton-Jansen et al, 1994). In addition, other studies have
reported that repression of E-cadherin transcription preceded
the subsequent acquisition of methylated CpG sites (Graff et al,
1995; Baranwal and Alahari, 2009). Loss of heterozygosity or
promoter methylation at the E-cadherin locus might be respon-
sible for the decrease of E-cadherin expression in breast cancer
patients.
E-cadherin-positive cases at stage II have better prognosis than
those at stage I. Out of 155 E-cadherin-positive patients at stage I,
3 were dead because of lung metastasis, whereas no patient with
E-cadherin-positive tumours at stage II was dead. Such three
patients did not receive any adjuvant chemotherapy. Adjuvant
chemotherapy might be necessary for breast cancer patients at
stage I. The number of patients with stage III disease might be
insufficient for the estimation of statistical difference in this study,
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Figure 2 Survival of patients with triple-negative breast cancer. (A) Correlation between the E-cadherin expression and either the overall survival
or disease-free interval in the triple-negative phenotype. (B, C) The overall survival or disease-free interval according to the clinical stage.
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slarge numbers of patients with stage III disease might be necessary
in future to conclude the significance of E-cadherin in patients
with stage III disease.
In the 123 TNBC cases in this study, the prognosis of patients
with E-cadherin-negative expression was significantly worse than
that of E-cadherin-positive patients, especially in cases of stage II
TNBC. As TNBC is a heterogeneous group of breast cancers, the
clinical course of TNBC patients remains difficult to predict
(Alizadeh et al, 2001). Therefore, additional markers are being
studied to further refine disease classification, especially in patient
subgroups the outcome of which cannot be accurately predicted
using conventional parameters. Although E-cadherin failed to
emerge as a prognostic factor in the 574 breast cancer cases, it was
successful in identifying a poor prognosis subgroup of TNBC
patients with E-cadherin expression. Our study showed that the
reduction of E-cadherin expression was an independent prognostic
factor in TNBC. These findings suggest that E-cadherin might be a
useful predictive marker to classify prognostic subgroups of TNBC
and to better understand these tumours. A close correlation
between lymph node metastasis and E-cadherin dysfunction has
been reported in various types of carcinomas. The frequent lymph
node metastasis associated with TNBC might be explained by the
loss of cell–cell adhesion due to E-cadherin dysfunction. The
association between E-cadherin and ER promoter methylation has
been previously reported in human breast tumours and correlates
with clinical parameters (Graff et al, 1995; Li et al, 2006; Baranwal
and Alahari, 2009). Promoter methylation may explain the
correlation between the reduction of E-cadherin expression and
ER-negative breast cancer.
In conclusion, 123 cases of TNBCs among 574 breast cancer
patients showed a poor prognosis, and TNBC was demonstrated to
be an independent prognostic factor. Furthermore, reduction of
E-cadherin expression was an independent prognostic factor for
TNBC. E-cadherin might be a useful predictive marker to classify
prognostic subgroups of TNBC and to better understand these
tumours.
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